Who
Joseph Todisco
Director
Company insider
Files Form 4 as: Director, Talphera; Chief Executive Officer, CorMedix; Executive Vice President, Amneal Pharmaceuticals.
In numbers
- Trades disclosed
- 93
- Buys
- 8
- Sells
- 4
- Bought
- $532K
- Sold
- $1.3M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 7 May 2019
- Last trade
- 22 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 24 Jun 2026 | TLPH TalpheraBiotechnology | SEC FORM 4 Code A | —5,100 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,700 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,700 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | TLPH TalpheraBiotechnology | SEC FORM 4 Code A | —5,100 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —77,156 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —77,156 at $0.00 | filing |
| 23 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —225,900 at $0.00 | filing |
| 23 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $199K27,306 at $7.27 | filing |
| 23 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —225,900 at $0.00 | filing |
| 23 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $199K27,306 at $7.27 | filing |
| 17 Jan 2026filed 20 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $154K22,665 at $6.78 | filing |
| 17 Jan 2026filed 20 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $154K22,665 at $6.78 | filing |
| 16 Jan 2026filed 20 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code M | $100K29,585 at $3.38 | filing |
| 16 Jan 2026filed 20 Jan 2026 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —29,585 at $0.00 | filing |
| 16 Jan 2026filed 20 Jan 2026 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —29,585 at $0.00 | filing |
| 16 Jan 2026filed 20 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code M | $100K29,585 at $3.38 | filing |
| 12 Jan 2026filed 20 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $125K17,417 at $7.15 | filing |
| 12 Jan 2026filed 20 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $125K17,417 at $7.15 | filing |
| 18 Dec 2025filed 19 Dec 2025 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —30,000 at $0.00 | filing |
| 18 Dec 2025filed 19 Dec 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code M | $133K30,000 at $4.43 | filing |
News
Head-To-Head Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus CorMedix (NASDAQ:CRMD)CRMD · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Joseph Todisco; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.